Antibody-drug conjugates for the treatment of human immunodeficiency virus (HIV) infection

An antibody-drug conjugate targeting CD4 activates latent HIV reservoirs, addressing the limitations of current treatments by expelling latent HIV, thereby potentially curing the infection.

JP2026517996APending Publication Date: 2026-06-02TAIMED BIOLOGICS
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
TAIMED BIOLOGICS
Filing Date
2024-05-31
Publication Date
2026-06-02

Smart Images

  • Figure 2026517996000031
    Figure 2026517996000031
  • Figure 2026517996000032
    Figure 2026517996000032
  • Figure 2026517996000033
    Figure 2026517996000033
Patent Text Reader

Abstract

The present invention provides an antibody-drug conjugate (ADC) for treating HIV infection, comprising an antibody that binds to CD4 and conjugated via a linker to one or more small molecule drugs capable of treating or preventing HIV infection.
Need to check novelty before this filing date? Find Prior Art